Table 1.

Percentage (with 95% confidence intervals) of participants reporting fever^a of any severity in the 7 days (day 0 to day 6) following administration of CSL's seasonal trivalent influenza vaccine, and one control comparator, by dose and age group

Study and vaccine	Dose	Age cohorts
		≥6 months to <3 years	≥3 to <9 years [≥3 to <5 years/≥5 to <9 years]	≥9 to <18 years
Study: Nolan et al.18 , b
2005 trivalent Southern Hemisphere vaccine	2005	n = 151	n = 147	n = 0c
	Dose one	23 (17–31)	16 (11–23) [23 (15–35)/10 (5–18)]	–
	Dose two	23 (17–30)	8 (5–14) [(17 (10–29)/1 (0–7)]	–
2006 trivalent Southern Hemisphere vaccine	2006	n = 76	n = 197	n = 0c
	Single booster dose	39 (29–51)	27 (21–33) [41 (32–50)/12 (7–21)]	–
Study: safety profile of CSL Limited's influenza virus vaccine compared to a US licensed comparator influenza virus vaccine19
2009/2010 trivalent Northern Hemisphere vaccine		n = 231	n = 254	n = 254
	Dose one	37 (31–43)	22 (17–28) [32 (23–43)/16 (11–22)]	6 (4–10)
	Dose two	15 (11–20)	2 (1–5) [14 (9–23)/0 (0–2)]	–d
Comparator split‐virion vaccine (Fluzone)		n = 228	n = 257	n = 250
	Dose one	14 (10–19)	9 (6–13) [11 (6–19)/9 (6–14)]	4 (2–7)
	Dose two	14 (10–19)	2 (1–4) [16 (10–25)/2 (1–5)]	–d
This study
2009 trivalent Southern Hemisphere vaccine		n = 710	n = 880	n = 402
	Dose one	29 (26–32)	19 (17–22) [28 (24–33)/14 (11–17)]	5 (3–8)
	Dose two	18 (15–21)	10 (8–12) [13 (10–17)/7 (5–10)]	–d

^aFever defined as temperature measured ≥37·5°C (axillary) or ≥38·0°C (oral).

^b≥3 to <9 years Cohort18 divided into ≥3 to <5 years and ≥5 to <9 years for comparison to other study.19

^cThis age group not in study.

^dAnnual single dose only required in this age group.